1. Academic Validation
  2. Functional redundancy of HSPA1, HSPA2 and other HSPA proteins in non-small cell lung carcinoma (NSCLC); an implication for NSCLC treatment

Functional redundancy of HSPA1, HSPA2 and other HSPA proteins in non-small cell lung carcinoma (NSCLC); an implication for NSCLC treatment

  • Sci Rep. 2019 Oct 7;9(1):14394. doi: 10.1038/s41598-019-50840-7.
Damian Robert Sojka 1 Agnieszka Gogler-Pigłowska 1 Natalia Vydra 1 Alexander Jorge Cortez 1 Piotr Teodor Filipczak 1 2 Zdzisław Krawczyk 1 Dorota Scieglinska 3
Affiliations

Affiliations

  • 1 Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie Institute - Oncology Center Gliwice Branch, 44-101, Gliwice, Poland.
  • 2 Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, New Mexico, 87108, USA.
  • 3 Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie Institute - Oncology Center Gliwice Branch, 44-101, Gliwice, Poland. [email protected].
Abstract

Heat shock proteins (HSPs) are a large group of chaperones considered critical for maintaining cellular proteostasis. Their aberrant expression in tumors can modulate the course of processes defined as hallmarks of Cancer. Previously, we showed that both stress-inducible HSPA1 and testis-enriched HSPA2, highly homologous members of the HSPA (HSP70) family, are often overexpressed in non-small cell lung carcinoma (NSCLC). HSPA1 is among the best characterized cancer-related chaperones, while the significance of HSPA2 for Cancer remains poorly understood. Previously we found that in primary NSCLC, HSPA1 was associated with good prognosis while HSPA2 correlated with bad prognosis, suggesting possible different roles of these proteins in Cancer. Therefore, in this work we investigated the impact of HSPA1 and HSPA2 on NSCLC cell phenotype. We found that neither paralog-selective nor simultaneous knockdown of HSPA1 and HSPA2 gene expression reduced growth and chemoresistance of NSCLC cells. Only blocking of HSPA proteins using pan-HSPA inhibitors, VER-155008 or JG-98, exerted potent Anticancer effect on NSCLC cells, albeit the final outcome was cell type-dependent. Pan-HSPA inhibition sensitized NSCLC cells to bortezomib, but not to platinum derivates. Our result suggests the inhibitors of Proteasome and HSPAs seem an effective drug combination for pre-clinical development in highly aggressive NSCLC.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-117282
    99.75%, Hsp70 Inhibitor